Abstracts

Post-Treatment Controllers Have Particular NK Cells With High Anti-HIV Capacity: VISCONTI Study

Background: The association of T-cells with the control of HIV infection has been well documented. In addition, several studies pointed out the role on innate immune responses in the resistance or delay to HIV disease progression. The recent description (VISCONTI study) of a group of patients, so-called post-treatment controllers (PTCs), who remains with undetectable viral…

In Vitro Replication and Interferon-Alpha Resistance of Transmitted HIV-1 Variants

Background: Despite the diverse quasispecies of HIV-1 in the transmitting partner, a bottleneck occurs during transmission whereby, in general, a single genetic variant from that quasispecies establishes infection in the new host. The current working model explaining the transmission bottleneck suggests that transmitted/founder (TF) variants have a higher in vivo fitness and are preferentially resistant…

HVTN505 Breakthrough Sequences Show HIV Vaccine-Associated Differences in Env-gp120

Background: The HVTN505 HIV vaccine study enrolled 2,504 US participants in a phase IIb test-of-concept efficacy trial of a DNA/rAd5 vaccine expressing Gag/Pol/Nef from subtype B and Env proteins from subtypes A/B/C. Although the vaccine showed no efficacy with respect to HIV acquisition or post-infection viral load (Hammer, NEJM, 2013), we analyzed breakthrough HIV isolates…

Randomized Clinical Trial of Antiretroviral Therapy for Prevention of HAND

Background: Neurocognitive (NC) impairment (NCI) is common among treated HIV+ adults and can occur for several reasons, including production of viral proteins in the CNS, neuroinflammation, and antiretroviral therapy (ART) neurotoxicity. To date, clinical trials have focused on treatment of existing NCI and have been largely inconclusive. We conducted a clinical trial to determine whether…

Neurocognitive Function in Africans Failing First-Line ART and Responses to Second Line

Background: Neurocognitive impairment is an important co-morbidity in HIV infection. Data describing neurocognitive function in patients from sub-Saharan Africa are generally sparse, with only limited data describing neurocognitive function at the time of failure of first-line therapy, and none describing the changes in neurocognitive function in response to second-line therapy. Methods: We studied patients who…

Compartmentalized HIV Rebound in the CNS After ART Interruption

Background: If strategies currently in development succeed in eradicating HIV reservoirs in peripheral blood and lymphoid tissues, residual sources of virus may remain in anatomic compartments, including the central nervous system (CNS). To design effective eradication strategies, it is crucial to determine to what extent compartmentalized HIV reservoirs contribute to viral rebound after antiretroviral therapy…

IRF4 Transcription Factor Associated With Integrated HIV DNA in Brain Macrophages

Background: Integrated HIV DNA (HIVint) can become transcriptionally silenced and latently expressed in certain types of resting lymphocytes. In the brain viral infection occurs predominantly in macrophage type cells in which viral latency is not as thoroughly investigated. To identify the cellular targets of eradication therapy in the CNS we compared macrophage markers in human…